Koen De Witte is the managing director of reMYND NV/ LLC, director at LeuvenInc and more broadly support(er)ing the Flemish/ Belgian biotech scene. reMYND is a clinical stage company developing novel treatments for Alzheimer’s, Huntington’s, epilepsy, ALS and other neurodegenerative diseases, backed by a proprietary drug discovery platform. The lead AD program is entering Phase 2, with the potential to cure Alzheimer’s.
Before joining reMYND, Koen was an Associate Partner at McKinsey & company and part of the Global Leadership of its Pharmaceutical and Healthcare practices. Koen helped his clients to introduce new products and to establish new businesses.
Koen holds a M.SC. from the University of Ghent in Belgium, a M.Sc. from MIT in the US, and an M.B.A. from Insead in France.